<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Doseology Sciences, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/doseology-sciences-inc</link>
    <description>Latest news and press releases for Doseology Sciences, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 30 Mar 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/doseology-sciences-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683683c078dffbe2df16967e.webp</url>
      <title>Doseology Sciences, Inc.</title>
      <link>https://6ix.com/company/doseology-sciences-inc</link>
    </image>
    <item>
      <title>Doseology Announces $2M Financing to Accelerate Commercialization of Oral Stimulant Pouch Platform</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-announces-dollar2m-financing-to-accelerate-commercialization-of-oral-stimulant-pouch-platform</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-announces-dollar2m-financing-to-accelerate-commercialization-of-oral-stimulant-pouch-platform</guid>
      <pubDate>Mon, 30 Mar 2026 11:00:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD |OTCQB: DOSEF | FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;) a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announces that it has arranged a non-brokered private placement of up to 3,225,806 units (each, a &quot;Unit&quot;) at a price of $0.62 per Unit to raise aggregate gross proceeds of up to $2,000,000 (the &quot;Offering&quot;).</description>
    </item>
    <item>
      <title>Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-uplists-to-otcqb-as-dosef-expanding-us-investor-access-to-the-emerging-oral-stimulant-pouch-category</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-uplists-to-otcqb-as-dosef-expanding-us-investor-access-to-the-emerging-oral-stimulant-pouch-category</guid>
      <pubDate>Wed, 11 Mar 2026 11:00:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;) a consumer product innovation company focused on oral stimulant pouch technologies, is pleased to announce that its common shares have commenced trading on the OTCQB® Venture Market in the United States under the symbol DOSEF.</description>
    </item>
    <item>
      <title>Doseology Launches Feed That Brain® Oral Stimulant Pouches in the U.S. Through Direct-to-Consumer Pilot</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-launches-feed-that-brainr-oral-stimulant-pouches-in-the-us-through-direct-to-consumer-pilot-7</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-launches-feed-that-brainr-oral-stimulant-pouches-in-the-us-through-direct-to-consumer-pilot-7</guid>
      <pubDate>Wed, 04 Mar 2026 12:00:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;) today announced the launch of the Feed That Brain® Energy Pouches, marking the Company&apos;s first direct-to-consumer pilot program in the United States.</description>
    </item>
    <item>
      <title>Doseology Appoints Larry Latowsky as Executive Chairman of the Board of Directors</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-appoints-larry-latowsky-as-executive-chairman-of-the-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-appoints-larry-latowsky-as-executive-chairman-of-the-board-of-directors</guid>
      <pubDate>Fri, 20 Feb 2026 12:00:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;) is pleased to announce the appointment of Larry Latowsky as a director and the Executive Chairman of its Board of Directors, effective February 18, 2026.</description>
    </item>
    <item>
      <title>Doseology Begins Pilot Production of Caffeine-Based Energy Pouches as Feed That Brain® Enters Oral Stimulant Format</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-begins-pilot-production-caffeine-141700276</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-begins-pilot-production-caffeine-141700276</guid>
      <pubDate>Wed, 21 Jan 2026 14:17:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;) a leader in biotechnology-driven consumer products, today announced the initiation of a pilot production run of non-nicotine, caffeine-based energy pouches under its wholly owned Feed That Brain® brand.</description>
    </item>
    <item>
      <title>The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/compliance-imperative-regulatory-moats-driving-171000432</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/compliance-imperative-regulatory-moats-driving-171000432</guid>
      <pubDate>Mon, 19 Jan 2026 17:10:00 GMT</pubDate>
      <description>The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes environment, commercial survival is no longer just about the product; it hinges on precision regulatory execution. Eight key regulatory and compliance pressures[2] are reshaping sector strategy, forcing a capital rotation into a first-mover cohort that includes Doseology Sciences Inc. (CSE: MOOD) (OTCPK:DOSEF) (FSE: VU70), Philip Morris (NYSE: PM), Celsiu</description>
    </item>
    <item>
      <title>Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-files-annual-information-form-160100339</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-files-annual-information-form-160100339</guid>
      <pubDate>Fri, 16 Jan 2026 16:01:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;) a leader in biotechnology-driven consumer products, today announced that it has filed its Annual Information Form (&quot;AIF&quot;), a key Canadian public-company disclosure document, for the fiscal year ended June 30, 2025 on SEDAR+.</description>
    </item>
    <item>
      <title>Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-engages-mckinney-regulatory-science-120000308</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-engages-mckinney-regulatory-science-120000308</guid>
      <pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;) a leader in biotechnology-driven consumer products, today announced a strategic partnership with McKinney Regulatory Science Advisors (&quot;McKinney&quot;), a premier FDA regulatory consulting firm specializing in nicotine and reduced-risk consumer products, to spearhead its regulatory submission strategy and solidify its commitment to scientific leadership in the oral pouch technology space.</description>
    </item>
    <item>
      <title>Doseology Announces Launch of Corporate Communications Program</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-announces-launch-corporate-communications-120000194</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-announces-launch-corporate-communications-120000194</guid>
      <pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
      <description>KELOWNA, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)(“Doseology” or the “Company”) is pleased to announce the launch of its Investor Communications Initiative, designed to strengthen disclosure practices, expand investor engagement, and support the Company’s long-term commercial and capital-markets strategy. The program includes a three (3) month engagement with Guerilla Capital, with an option to renew, along with a one (1) y</description>
    </item>
    <item>
      <title>Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-completes-extensive-north-american-090000408</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-completes-extensive-north-american-090000408</guid>
      <pubDate>Thu, 13 Nov 2025 09:00:00 GMT</pubDate>
      <description>KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is pleased to announce that its wholly owned Florida subsidiary, Doseology USA Inc., has executed a confidential manufacturing agreement with a leading North American production partner. This milestone represents a step in Doseology’s operational evolution—establishing the commercial infras</description>
    </item>
    <item>
      <title>Doseology Completes Acquisition of Feed That Brain™</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-completes-acquisition-feed-brain-110000947</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-completes-acquisition-feed-brain-110000947</guid>
      <pubDate>Wed, 27 Aug 2025 11:00:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;), an innovator in precision-formulated oral stimulants, is pleased to announce that, further to its news release of August 19, 2025, it has closed the acquisition of the &quot;Feed That Brain&quot; division operated by Joseph Mimran &amp; Associates Inc. (the &quot;Vendor&quot;) and has completed the issuance to the Vendor of 175,000 common shares (each a &quot;Share&quot;) at a deemed price of $1.00 per Share satisfying the first payment</description>
    </item>
    <item>
      <title>Doseology Acquires Feed That Brain™ and Appoints Joseph Mimran as Strategic Advisor</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-acquires-feed-brain-appoints-110000730</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-acquires-feed-brain-appoints-110000730</guid>
      <pubDate>Tue, 19 Aug 2025 11:00:00 GMT</pubDate>
      <description>Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) (&quot;Doseology&quot; or the &quot;Company&quot;), an innovator in precision-formulated oral stimulants, is pleased to announce that it has entered into an asset purchase and sale agreement (the &quot;Asset Purchase Agreement&quot;) to acquire the &apos;Feed That Brain&apos; division (the &quot;FTB Assets&quot;) operated by Joseph Mimran &amp; Associates Inc. (the &quot;Vendor&quot;) for aggregate consideration of $400,000 (the &quot;Purchase Price&quot;) (the &quot;Transaction&quot;).</description>
    </item>
    <item>
      <title>CSE Bulletin: Consolidation - Doseology Sciences Inc. (MOOD)</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/cse-bulletin-consolidation-doseology-sciences-inc-mood</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/cse-bulletin-consolidation-doseology-sciences-inc-mood</guid>
      <pubDate>Tue, 13 Feb 2024 16:14:00 GMT</pubDate>
      <description>Toronto, Ontario--(Newsfile Corp. - Le 13 f&amp;#xE9;vrier/February 2024) - Doseology Sciences Inc. h...</description>
    </item>
    <item>
      <title>Doseology Grows Canadian Retail Sales with Loblaw Companies</title>
      <link>https://6ix.com/company/doseology-sciences-inc/news/doseology-grows-canadian-retail-sales-with-loblaw-companies</link>
      <guid isPermaLink="true">https://6ix.com/company/doseology-sciences-inc/news/doseology-grows-canadian-retail-sales-with-loblaw-companies</guid>
      <pubDate>Thu, 28 Sep 2023 11:30:00 GMT</pubDate>
      <description>(TheNewswire)       Kelowna, British Columbia &amp;#x2013;     TheNewswire -     Sept. 28, 2023 &amp;#x20...</description>
    </item>
  </channel>
</rss>